Abstract:12126 Background: The study was to evaluate the equivalence of LY01011 to the reference product denosumab in terms of reduction of bone metabolism markers. Methods: Eligible patients were randomized at 1:1 ratio to receive 120 mg LY01011 injection or 120 mg denosumab every four weeks subcutaneously. Following the completion of three doses of 120 mg LY01011 or denosumab in a 12-week double-blind treatment period (DBTP), all enrolled patients would continue to receive LY01011 administration until the week 53 of follow-up period. The primary end point was the natural logarithm change at week 13 from baseline in urinary cross-linked N terminal telopeptide of type I collagen, corrected for urine creatinine (uNTx/uCr). The equivalence between LY01011 and denosumab would be concluded if the 90% CI was completely inside the pre-defined equivalence boundary between -0.135 and 0.135. A formal blinded sample-size re-estimation (BSSR) was planned to take place once 60% of the planned participants had completed the Week 13 assessments. After BSSR, the sample size increased from 560 to 850 according to prespecified procedure based on pooled standard deviationfrom the blinded data, which was set as a cap to ensure a feasible sample size for the study and no need to do any multiplicity adjustment. Results: All eligible 850 patients, included in the full analysis set, were randomized into the LY01011 group (n = 424) and denosumab group (n = 426). The samples from the 12-week DBTP were collected for analysis in both groups. The least square mean (LSM) (SE) of the natural logarithm change of uNTX/uCr at week 13 from baseline was -1.740 (0.0420) in the LY01011 group and -1.745 (0.0421) in denosumab group. The LSM difference was 0.005 between LY01011 and denosumab groups with 90% CI of [-0.088, 0.097] (p > 0.05). Skeletal related events occurring in the LY01011 and denosumab groups were 3.5% and 2.8%, respectively. The mean (SD) percentage changes of serum bone-specific alkaline phosphatase (s-BALP) from baseline to week 13 were -31.154% (39.6790) and -33.021% (37.3826) in the LY01011 and denosumab groups, respectively. The median was -36.866% and -37.457% (p > 0.05). The incidence of treatment-emergent adverse events (TEAEs) of any grade was 91.7% and 90.8% in LY01011 and denosumab groups(p > 0.05). Both groups had 38.4% of Grade ≥3 TEAEs, of which 5.4% (LY01011) and 4.5% (denosumab) were judged to be related to the study drug. Immunogenicity analysis showed that no participant (0/399) had a positive ADA test in denosumab group and only one participant (0.2%, 1/401) was tested ADA positive in LY01011 group. Conclusions: The study demonstrated the equivalent efficacy of LY01011 in the reduction of bone metabolism biomarker NTX to reference product, denosumab, which met the primary endpoint. It had a good safety profile with no unexpected adverse reactions in the study. Clinical trial information: NCT04859569 .

Efficacy and Safety of Denosumab from A Phase Iii, Randomized, Active-Controlled Study Compared with Zoledronic Acid in Patients of Asian Ancestry with Bone Metastases from Solid Tumors.

Efficacy and Safety of Denosumab in Postmenopausal Women with Osteoporosis

Comparison of efficacy and safety of denosumab versus zoledronic acid for treating skeletal-related events caused by bone metastasis in patients with maligmant solid tumors and multiple myeloma: A Meta-analysis of randomized controlled trials

Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials

Efficacy and Safety of Denosumab Versus Zoledronic acid in Suppressing Bone Metastases of Breast Cancer

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Comparison of Clinical Efficacy and Safety Between Denosumab and Alendronate in Postmenopausal Women with Osteoporosis: a Meta-Analysis

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials

Real-world Data of Efficacy and Safety of Denosumab on Patients with Breast Cancer with Bone Metastasis: Results from Chinese Clinical Experience.

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk

[Phase III Clinical Study of Zoledronic Acid in the Treatment of Pain Induced by Bone Metastasis from Solid Tumor or Multiple Myeloma].

[Analysis of the efficacy and safety of bone disease treatment in patients with newly diagnosed multiple myeloma treated with denosumab or zoledronic acid]

The Skeletal-Related Events of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials.

Safety of Denosumab Versus Zoledronic Acid in Patients with Bone-related Diseases A Systematic Review and Meta-analysis

A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients with Breast Cancer.

Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study

Effect of denosumab , a fully human monoclonal antibody to RANKL , on bone mineral density and fractures : a meta-analysis

Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 study.

Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China.

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.